Viamet Pharmaceuticals® discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, our Metallophile™ Technology. Viamet's disruptive Metallophile™ technology is based on our world-class expertise in bioinorganic chemistry and metalloenzymes and allows us to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors. The Metallophile™ Technology has enabled Viamet to rapidly build a portfolio of proprietary drug candidates and leads which represent blockbuster potential.
.